EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-Term Outcomes of Apixaban as Main Anticoagulant in Patients with HeartMate 3 Left Ventricular Assist Devices

Jennifer Jdaidani, Mahmoud Shadi, Nnedi Asogwa, Jennifer Winik, Dora Rossi, Christina Saikus, Maria D Avila, Geurys R Rojas-Marte iD

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Jennifer Jdaidani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Staten Island University Hospital, Northwell Health, New Hyde Park, New York, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Pyridones, Pyrazoles, Heart Failure. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility-related outcomes for end-stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin. This study presents a long-term evaluation of thrombotic and bleeding outcomes in HM3 LVAD patients transitioned from warfarin to apixaban.

Methods

We retrospectively identified HM3 LVAD patients at our single centre who transitioned from warfarin to apixaban. Baseline characteristics were described at discharge from implant hospitalization and at the last follow-up on each anticoagulation regimen. We reported survival, thrombo-embolic events (including LVAD pump thrombosis, stroke, arterial thrombo-embolic events and pump exchange) and bleeding events on both warfarin and apixaban.

Results

Eight patients were identified between May 2018 and June 2022 who transitioned from warfarin to apixaban 5 mg twice daily. Patients were followed for a mean of 1233 days after LVAD implantation and 789 days after transition to apixaban. All patients were transitioned due to difficulty maintaining a therapeutic international normalized ratio (INR), including five patients who experienced bleeding complications on warfarin. No patients encountered LVAD pump thrombosis, stroke events, arterial thrombo-embolic event, pump exchange or death. While on warfarin, five patients had eight bleeding events: one major [requiring 2 units of packed red blood cells (pRBCs)] and seven minors (five gastrointestinal bleeds, one episode of haematuria and one episode of haemoptysis). After switching to apixaban, one patient with angioectasia had a major gastrointestinal bleed requiring two pRBCs and endoscopic clipping.

Conclusions

Apixaban demonstrated safe and favourable long-term outcomes in a cohort of HM3 LVAD patients over a mean follow-up of more than 2 years. To our knowledge, our report provides the longest follow-up duration for this patient population to date. Larger prospective studies are needed before this can be adopted as the standard of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesPyridonesPyrazolesHeart FailureThrombosisHumansMaleRetrospective StudiesFemaleMiddle AgedAnticoagulantsFollow-Up StudiesFactor Xa InhibitorsTime FactorsTreatment OutcomeAgedWarfarinAdult

Stichwörter der Autor:innen

HeartMate 3LVADadvanced heart failureapixabanleft ventricular assist devicewarfarin

Substanzen

apixabanPyridonesPyrazolesAnticoagulantsFactor Xa InhibitorsWarfarin

Autor:innen und Institutionen

  • Department of Internal Medicine, Staten Island University Hospital, Northwell Health, New Hyde Park, New York, USA.
  • Cardiovascular Institute, Staten Island University Hospital, Northwell Health, New Hyde Park, New York, USA.
  • Cardiovascular Institute, North Shore University Hospital, Northwell Health, New Hyde Park, New York, USA.
  • Cardiovascular and Thoracic Surgery, North Shore University Hospital, Northwell Health, New Hyde Park, New York, USA.

ORCID-Profile: Geurys R Rojas-Marte

Zitieren

APA

Jdaidani, J., Shadi, M., Asogwa, N., Winik, J., Rossi, D., Saikus, C., Avila, M. D., & Rojas-Marte, G. R. (2025). Long-Term Outcomes of Apixaban as Main Anticoagulant in Patients with HeartMate 3 Left Ventricular Assist Devices. ESC Heart Failure. https://doi.org/10.1002/ehf2.15182

Vancouver

Jdaidani J, Shadi M, Asogwa N, Winik J, Rossi D, Saikus C, et al. Long-Term Outcomes of Apixaban as Main Anticoagulant in Patients with HeartMate 3 Left Ventricular Assist Devices. ESC Heart Failure. 2025. doi:10.1002/ehf2.15182

BibTeX
@article{Jdaidani2025,
  author = {Jdaidani, Jennifer and Shadi, Mahmoud and Asogwa, Nnedi and Winik, Jennifer and Rossi, Dora and Saikus, Christina and Avila, Maria D and Rojas-Marte, Geurys R},
  title = {Long-Term Outcomes of Apixaban as Main Anticoagulant in Patients with HeartMate 3 Left Ventricular Assist Devices},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15182}
}
Kostenlos starten →